Tumor lysis syndrome Review article
Article Sidebar
Main Article Content
Abstract
Tumor lysis syndrome is a life-threatening oncological emergency occurring in response to chemotherapy or spontaneously as a result of massive and rapid breakdown of malignant cells. The release of their contents into circulation leads to a constellation of the characteristic metabolic abnormalities (hyperuricemia, hyperphosphatemia, hyperkalemia, hypocalcemia) and their clinical consequences such as acute kidney injury, cardiac arrythmias and death. The article summarizes the current knowledge on tumor lysis syndrome prophylaxis and treatment.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Ejaz A.A., Mu W., Kang D.H. et al.: Could uric acid have a role in acute renal failure? Clin. J. Am. Soc. Nephrol. 2007; 2: 16-21.
3. Soares M., Feres G.A., Salluh J.I.: Systemic inflammatory response syndrome and multiple organ dysfunction in patients with acute tumor lysis syndrome. Clinics (Sao Paulo) 2009; 64: 479-481.
4. LaRosa C., McMullen L., Bakdash S. et al.: Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatr. Nephrol. 2007; 22: 132-5.
5. Davidson M., Thakkar S., Hix J.K. et al.: Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am. J. Med. 2004; 116: 546-554.
6. Cairo M.S., Bishop M.: Tumour lysis syndrome: new therapeutic strategies and classification. Br. J. Haematol. 2004; 127: 3-11.
7. Howard S.C., Jones D.P., Pui C.H.: The tumor lysis syndrome: current concepts. N. Engl. J. Med. 2011; 364: 1844-1854.
8. Coiffier B., Altman A., Pui C.H. et al.: Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J. Clin. Oncol. 2008; 26: 2767-2778.
9. Bessmertny O., Robitaille L.M., Cairo M.S.: Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome. Curr. Pharm. Des. 2005; 11: 4177-4185.
10. Sood A.R., Burry L.D., Cheng D.K.: Clarifying the role of rasburicase in tumor lysis syndrome. Pharmacotherapy 2007; 27: 111-121.
11. Cairo M.S., Gerrard M., Sposto R. et al.: Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007; 109: 2736-2743.
12. Coiffier B., Mounier N., Bologna S. et al.: Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin’s lymphoma: results of the GRAAL1 study. J. Clin. Oncol. 2003; 21: 4402-4412.
13. Hummel M., Reiter S., Adam K. et al.: Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase. Eur. J. Haematol. 2008; 80: 331-339.
14. Vadhan-Raj S., Fayad L.E., Fanale M.A. et al.: A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann. Oncol. 2012 Jun; 23(6): 1640-5.